Portal de Periódicos da CAPES

Prostate Specific Antigen after Gonadal Androgen Withdrawal and Deferred Flutamide Treatment

1995; Lippincott Williams & Wilkins; Volume: 154; Issue: 2 Linguagem: Inglês

10.1016/s0022-5347(01)67071-x

1527-3792

Jackson E. Fowler, Prabhakar Pandey, Linda E. Seaver, Tony P. Feliz,

Urologic and reproductive health conditions

No AccessJournal of UrologyClinical Urology: Original Article1 Aug 1995Prostate Specific Antigen after Gonadal Androgen Withdrawal and Deferred Flutamide Treatment Jackson E. Jr. Fowler, Prabhakar Pandey, Linda E. Seaver, and Tony P. Feliz Jackson E. Jr. FowlerJackson E. Jr. Fowler More articles by this author , Prabhakar PandeyPrabhakar Pandey More articles by this author , Linda E. SeaverLinda E. Seaver More articles by this author , and Tony P. FelizTony P. Feliz More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)67071-XAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We assess the impact of deferred flutamide treatment on the serum prostate specific antigen (PSA) level in patients with localized or metastatic cancer. Materials and Methods: The study included 45 patients with localized cancer and 50 with metastatic cancer with an increasing (87) or stable (8) PSA level after gonadal androgen withdrawal. Results: Of 40 evaluable patients with localized cancer and 50 with metastatic cancer 32 (80 percent) and 27 (54 percent), respectively, had a PSA decrease of 50 percent or more of baseline during flutamide treatment (p = 0.014). Among patients with localized cancer actuarial analysis of freedom from PSA elevation during flutamide treatment favored those with a 50 percent or greater PSA decrease (p = 0.006) but in patients with metastatic cancer the analysis revealed no significant difference. Conclusions: The relative density of tumor cells that are dependent on adrenal androgen after gonadal androgen withdrawal may be greater in patients with localized cancer and deferred flutamide treatment may enhance cancer control in those with localized disease. References 1 : Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer1991; 67: 3057. Google Scholar 2 : Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer. J. Urol.1990; 144: 1177. Link, Google Scholar 3 : Flutamide in hormone-resistant prostatic cancer. J. Urol.1990; 144: 1411. Abstract, Google Scholar 4 : PSA correlation with response and survival in advanced carcinoma of the prostate. J. Urol., part 21993; 149: 430A. abstract 868. Google Scholar 5 : A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Engl. J. Med.1989; 321: 419. Google Scholar 6 : Zoladex plus flutamide vs. orchidectomy for advanced prostate cancer. Danish Prostatic Group (DAPROCA). Eur. Urol.1990; 18: 41. Google Scholar 7 : Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinoma: interim report of a multicenter, double-blind, placebo-controlled study. Eur. Urol.1990; 18: 45. Google Scholar 8 : Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP). Eur. Urol.1990; 18: 48. Google Scholar 9 : Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian Study. Eur. Urol.1990; 18: 54. Google Scholar 10 : Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology1993; 42: 119. Google Scholar 11 : Histologic grading of primary prostatic cancer: a new approach to an old problem. J. Urol.1980; 123: 689. Link, Google Scholar 12 : Prostate specific antigen progression rates after radical prostatectomy or radiation therapy for localized prostate cancer. Surgery1994; 116: 302. Google Scholar 13 : Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J. Clin. Oncol.1993; 11: 607. Google Scholar 14 : The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. J. Urol.1989; 141: 987. Link, Google Scholar 15 : Editorial comment. J. Urol.1992; 147: 290. Google Scholar 16 : The use of flutamide in hormone-refractory metastatic prostate cancer. Cancer1993; 72: 3870. Google Scholar 17 : The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J. Urol.1992; 147: 956. Link, Google Scholar 18 : Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. Natl. Cancer Inst. Monogr.1988; 7: 165. Google Scholar 19 : Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment. A Medical Research Council study. Urological Cancer Working Party–Subgroup on Prostatic Cancer. Brit. J. Urol.1992; 70: 304. Google Scholar 20 : Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. J. Urol.1993; 150: 400. Link, Google Scholar 21 : Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer1992; 70: 2302. Google Scholar 22 : Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer. J. Urol.1995; 153: 1860. Link, Google Scholar 23 : Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol.1993; 11: 1566. Google Scholar 24 : Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol.1993; 150: 908. Link, Google Scholar Division of Urology, University of Mississippi Medical Center, Jackson, Mississippi.Accepted for publication January 6, 1995© 1995 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byLam J, Leppert J, Vemulapalli S, Shvarts O and Belldegrun A (2018) Secondary Hormonal Therapy for Advanced Prostate CancerJournal of Urology, VOL. 175, NO. 1, (27-34), Online publication date: 1-Jan-2006.Fowler J, Bigler S, Renfroe D and Dabagia M (2018) Prostate Specific Antigen in Black and White Men After Hormonal Therapies for Prostate CancerJournal of Urology, VOL. 158, NO. 1, (150-154), Online publication date: 1-Jul-1997. Volume 154Issue 2August 1995Page: 448-453 Advertisement Copyright & Permissions© 1995 by American Urological Association, Inc.MetricsAuthor Information Jackson E. Jr. Fowler More articles by this author Prabhakar Pandey More articles by this author Linda E. Seaver More articles by this author Tony P. Feliz More articles by this author Expand All Advertisement PDF downloadLoading ...